• LAST PRICE
    189.2300
  • TODAY'S CHANGE (%)
    Trending Down-4.0600 (-2.1005%)
  • Bid / Lots
    186.0000/ 1
  • Ask / Lots
    194.9900/ 1
  • Open / Previous Close
    187.7900 / 193.2900
  • Day Range
    Low 186.1600
    High 191.4500
  • 52 Week Range
    Low 126.9681
    High 248.1600
  • Volume
    273,898
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 193.29
TimeVolumeBGNE
09:32 ET11491188.99
09:33 ET600188.99
09:37 ET1256189.04
09:44 ET500188.85
09:46 ET100188.66
09:48 ET4386187.44
09:50 ET200187.825
09:51 ET300187.805
09:53 ET790188.46
09:55 ET500187.825
09:57 ET981187.73
10:00 ET900187.02
10:02 ET1000186.25
10:04 ET3164186.89
10:06 ET800187.515
10:08 ET1000187.36
10:09 ET900187.23
10:11 ET700186.98
10:13 ET2400187.5
10:15 ET1100188.235
10:18 ET200187.92
10:20 ET1213188.79
10:22 ET100187.905
10:24 ET200187.905
10:27 ET600188
10:29 ET3200188.1
10:31 ET400187.54
10:33 ET200186.97
10:36 ET200187.34
10:38 ET100186.94
10:40 ET436186.82
10:45 ET100186.6
10:47 ET800186.865
10:49 ET100186.9
10:51 ET500186.76
10:58 ET205186.65
11:00 ET1270186.73
11:03 ET200186.31
11:05 ET100186.23
11:07 ET565186.2211
11:14 ET100186.51
11:16 ET603187
11:18 ET100187.06
11:20 ET968187.1
11:21 ET1042187
11:23 ET200187.105
11:25 ET100187.17
11:27 ET2436187.41
11:30 ET500187.58
11:34 ET640187.5
11:36 ET200187.5
11:38 ET560187.5
11:39 ET300187.495
11:41 ET1200187.585
11:43 ET3740186.95
11:48 ET100186.54
11:50 ET100187.005
11:52 ET100187.015
11:56 ET100187.105
11:59 ET300187.37
12:03 ET100187.56
12:10 ET100187.8
12:12 ET1106187.58
12:14 ET500187.32
12:15 ET600187.515
12:17 ET500187.8775
12:19 ET1821187.98
12:21 ET225188.11
12:37 ET800187.66
12:50 ET373187.4623
12:51 ET100187.29
12:55 ET900187.1
12:57 ET100187.47
01:02 ET100187.54
01:04 ET100187.395
01:06 ET400187.2
01:08 ET4159187.76
01:09 ET521188.25
01:11 ET104188.19
01:15 ET100188.025
01:18 ET100188.04
01:22 ET200188.16
01:24 ET200188.38
01:26 ET200188.28
01:27 ET144188.046
01:31 ET1100188.68
01:33 ET100188.39
01:36 ET100188.29
01:38 ET100188.23
01:40 ET169188.3881
01:44 ET1500188.011
01:47 ET100188.18
01:49 ET1300188
01:51 ET100188.08
01:54 ET800187.88
01:56 ET100188.25
01:58 ET100187.92
02:02 ET300188.095
02:05 ET800188.42
02:07 ET100188.42
02:12 ET100188.4
02:16 ET100188.145
02:23 ET1165188.1
02:25 ET100187.99
02:30 ET500188.09
02:34 ET700188.1
02:41 ET924188.635
02:45 ET100188.8
03:15 ET100188.82
03:17 ET600188.78
03:19 ET1200188.97
03:26 ET300188.82
03:28 ET7824188.445
03:30 ET400188.445
03:32 ET300188.3325
03:35 ET1500188.6
03:37 ET2000188.58
03:42 ET4640188.745
03:44 ET300189.14
03:46 ET2382189.105
03:48 ET1267189.1
03:50 ET2191189.075
03:51 ET2021188.675
03:53 ET3040189.2
03:55 ET2304189.63
03:57 ET6719189.315
04:00 ET19890189.23
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBGNE
Beigene Ltd
21.4B
-23.0x
---
United StatesUTHR
United Therapeutics Corp
17.2B
16.0x
+8.22%
United StatesBMRN
BioMarin Pharmaceutical Inc
12.5B
38.1x
---
United StatesEXAS
Exact Sciences Corp
9.4B
-42.1x
---
United StatesNBIX
Neurocrine Biosciences Inc
12.4B
31.4x
+62.04%
United StatesINCY
Incyte Corp
15.0B
542.1x
+39.11%
As of 2024-11-15

Company Information

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Contact Information

Headquarters
C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
Phone
345-949-4123
Fax
---

Executives

Co-Founder, Executive Chairman of the Board, Chief Executive Officer
John Oyler
President, Chief Operating Officer, General Manager - China
Xiaobin Wu
Co-Founder, Non-Executive Director
Xiaodong Wang
Chief Financial Officer
Aaron Rosenberg
Senior Vice President, General Counsel
Chan Lee

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$21.4B
Revenue (TTM)
$3.3B
Shares Outstanding
106.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.55
EPS
$-8.24
Book Value
$36.95
P/E Ratio
-23.0x
Price/Sales (TTM)
6.5
Price/Cash Flow (TTM)
---
Operating Margin
-26.31%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.